ORBIMED ADVISORS LLC sold ELVN

June 22, 2026 · Form 4 insider transaction

ORBIMED ADVISORS LLC sold 787,024 shares of Enliven Therapeutics, Inc. at $45.38 per share, a transaction worth $35.72M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
787,024
Price
$45.38
Total value
$35.72M
Role
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJune 22, 2026
Filing dateJune 24, 2026
Shares owned after6,601,878
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.; This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR